
T
his biopharma superlative is a no-brainer: The most noteworthy drug approval of the year goes, hands-down, to the two CAR-T drugs that hit the market earlier this year.
Kymriah, from Novartis (NVS), was approved in late August, with a price tag set at $475,000. And Yescarta, developed by Kite Pharma and acquired by Gilead Sciences (GILD), was approved in October, with a $373,000 set price. Both work with just a single infusion.
pls. deliver me news about brain cancer treatment.